Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,401
archived clinical trials in
Alzheimer Disease

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Quantum Laboratories
960
mi
from 43215
Pompano Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Quantum Laboratories
960
mi
from 43215
Pompano Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute at Palm Beach Neurology
927
mi
from 43215
West Palm Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute at Palm Beach Neurology
927
mi
from 43215
West Palm Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Neurological Center
133
mi
from 43215
Fort Wayne, IN
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Neurological Center
133
mi
from 43215
Fort Wayne, IN
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
345
mi
from 43215
Baltimore, MD
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
345
mi
from 43215
Baltimore, MD
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Princeton Medical Institute
442
mi
from 43215
Princeton, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Princeton Medical Institute
442
mi
from 43215
Princeton, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Summit Research Network
2028
mi
from 43215
Portland, OR
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Summit Research Network
2028
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Center for Cognitive Health
2031
mi
from 43215
Portland, OR
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Center for Cognitive Health
2031
mi
from 43215
Portland, OR
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Abington Neurological Associates
417
mi
from 43215
Abington, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Abington Neurological Associates
417
mi
from 43215
Abington, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Northeastern Pennsylvania Memory and Alzheimer's Center
386
mi
from 43215
Plains, PA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Northeastern Pennsylvania Memory and Alzheimer's Center
386
mi
from 43215
Plains, PA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
FutureSearch Trials
905
mi
from 43215
Dallas, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
FutureSearch Trials
905
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
National Clinical Research - Richmond, Inc.
335
mi
from 43215
Richmond, VA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
National Clinical Research - Richmond, Inc.
335
mi
from 43215
Richmond, VA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
1669
mi
from 43215
Sun City, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
1669
mi
from 43215
Sun City, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Arizona Health Sciences Center
1639
mi
from 43215
Tucson, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Arizona Health Sciences Center
1639
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
MCB Clinical Research Centers
1163
mi
from 43215
Colorado Springs, CO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
MCB Clinical Research Centers
1163
mi
from 43215
Colorado Springs, CO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Neuroscience Solutions, Inc.
673
mi
from 43215
Jacksonville, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Neuroscience Solutions, Inc.
673
mi
from 43215
Jacksonville, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Compass Research LLC
795
mi
from 43215
Orlando, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Compass Research LLC
795
mi
from 43215
Orlando, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Alexian Brothers Medical Center
293
mi
from 43215
Elk Grove Village, IL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Alexian Brothers Medical Center
293
mi
from 43215
Elk Grove Village, IL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
The Cognitive and Research Center of NJ
460
mi
from 43215
Springfield, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
The Cognitive and Research Center of NJ
460
mi
from 43215
Springfield, NJ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Baylor AT&T Memory Center
910
mi
from 43215
Dallas, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Baylor AT&T Memory Center
910
mi
from 43215
Dallas, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Clinical Trials of Texas, Inc.
1137
mi
from 43215
San Antonio, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Clinical Trials of Texas, Inc.
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at San Antonio
1137
mi
from 43215
San Antonio, TX
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Parexel Early Phase Unit at Glendale
1967
mi
from 43215
Glendale, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Parexel Early Phase Unit at Glendale
1967
mi
from 43215
Glendale, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
California Pacific Medical Center
2108
mi
from 43215
San Francisco, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
California Pacific Medical Center
2108
mi
from 43215
San Francisco, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Care Access Research
1979
mi
from 43215
Santa Clarita, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Care Access Research
1979
mi
from 43215
Santa Clarita, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Care Access Research LLC
1980
mi
from 43215
Valencia, CA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Care Access Research LLC
1980
mi
from 43215
Valencia, CA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Mount Sinai Medical Center
991
mi
from 43215
Miami Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Mount Sinai Medical Center
991
mi
from 43215
Miami Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Miami Jewish Health Systems
990
mi
from 43215
Miami, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Miami Jewish Health Systems
990
mi
from 43215
Miami, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pensacola Research Consultants, Inc.
695
mi
from 43215
Pensacola, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pensacola Research Consultants, Inc.
695
mi
from 43215
Pensacola, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Roskamp Institute
868
mi
from 43215
Sarasota, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Roskamp Institute
868
mi
from 43215
Sarasota, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Christie Clinic
276
mi
from 43215
Champaign, IL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Christie Clinic
276
mi
from 43215
Champaign, IL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Central DuPage Hospital
298
mi
from 43215
Winfield, IL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Central DuPage Hospital
298
mi
from 43215
Winfield, IL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Josephson Wallack Munshower Neurology P.C
158
mi
from 43215
Indianapolis, IN
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Josephson Wallack Munshower Neurology P.C
158
mi
from 43215
Indianapolis, IN
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Baptist Health Medical Group
157
mi
from 43215
Lexington, KY
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Baptist Health Medical Group
157
mi
from 43215
Lexington, KY
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Maine Neurology
699
mi
from 43215
Scarborough, ME
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Maine Neurology
699
mi
from 43215
Scarborough, ME
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research
642
mi
from 43215
Methuen, MA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research
642
mi
from 43215
Methuen, MA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Donald S. Marks, M.D., P.C.
658
mi
from 43215
Plymouth, MA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Donald S. Marks, M.D., P.C.
658
mi
from 43215
Plymouth, MA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ST. Luke's Hospital
619
mi
from 43215
Kansas City, MO
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ST. Luke's Hospital
619
mi
from 43215
Kansas City, MO
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Healthy Perspectives Innovative Mental Health Services, PL
629
mi
from 43215
Nashua, NH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Healthy Perspectives Innovative Mental Health Services, PL
629
mi
from 43215
Nashua, NH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
ActivMed Practices & Research, Inc.
668
mi
from 43215
Portsmouth, NH
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
ActivMed Practices & Research, Inc.
668
mi
from 43215
Portsmouth, NH
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Metrolina Neurological Research Institute
367
mi
from 43215
Indian Land, SC
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Metrolina Neurological Research Institute
367
mi
from 43215
Indian Land, SC
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Sentara Medical Group
427
mi
from 43215
Norfolk, VA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Sentara Medical Group
427
mi
from 43215
Norfolk, VA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Evergreen Professional Plaza
1999
mi
from 43215
Kirkland, WA
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Evergreen Professional Plaza
1999
mi
from 43215
Kirkland, WA
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Dean Foundation For Health Research & Education
399
mi
from 43215
Middleton, WI
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Dean Foundation For Health Research & Education
399
mi
from 43215
Middleton, WI
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from 43215
Gatineau,
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
mi
from 43215
Gatineau,
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Center for Neurosciences
1637
mi
from 43215
Tucson, AZ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Center for Neurosciences
1637
mi
from 43215
Tucson, AZ
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Brain Matters Research
948
mi
from 43215
Delray Beach, FL
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Brain Matters Research
948
mi
from 43215
Delray Beach, FL
Click here to add this to my saved trials
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Pyramid Clinical Research
455
mi
from 43215
Monroe, NJ
A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Pyramid Clinical Research
455
mi
from 43215
Monroe, NJ
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
Xenoscience Inc.
1662
mi
from 43215
Phoenix, AZ
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
Xenoscience Inc.
1662
mi
from 43215
Phoenix, AZ
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
NEA Baptist Clinical
506
mi
from 43215
Jonesboro, AR
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
NEA Baptist Clinical
506
mi
from 43215
Jonesboro, AR
Click here to add this to my saved trials
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated:  12/31/1969
California Research Foundation
1951
mi
from 43215
San Diego, CA
A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Status: Enrolling
Updated: 12/31/1969
California Research Foundation
1951
mi
from 43215
San Diego, CA
Click here to add this to my saved trials